Baxter Bros Inc Immuno Gen, Inc. Transaction History

Baxter Bros Inc

$762 Million
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 May 17, 2024	BUY	$12.46 - $29.95 $171,325 - $411,812	13,750 New	13,750 $407,000
Q3 2023 May 17, 2024	BUY	$14.09 - $19.87 $193,737 - $273,212	13,750 New	13,750 $218,000
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $269,250 - $1.44 Million	-71,800 Reduced 83.93%	13,750 $259,000
Q4 2022 Jan 31, 2023	SELL	$4.55 - $6.31 $6,597 - $9,149	-1,450 Reduced 1.67%	85,550 $424,000
Q1 2022 Apr 20, 2022	BUY	$4.26 - $7.48 $852 - $1,496	200 Added 0.23%	87,000 $414,000
Q4 2021 Jan 14, 2022	SELL	$4.75 - $7.5 $7,125 - $11,250	-1,500 Reduced 1.7%	86,800 $644,000
Q2 2021 Aug 11, 2021	BUY	$5.79 - $8.6 $8,685 - $12,900	1,500 Added 1.73%	88,300 $582,000
Q1 2021 Apr 23, 2021	SELL	$6.5 - $10.53 $3,250 - $5,265	-500 Reduced 0.57%	86,800 $703,000
Q4 2020 Jan 25, 2021	SELL	$3.7 - $7.66 $3,700 - $7,660	-1,000 Reduced 1.13%	87,300 $563,000
Q1 2020 Apr 17, 2020	BUY	$2.12 - $6.8 $21,200 - $68,000	10,000 Added 12.77%	88,300 $301,000
Q4 2019 Jan 10, 2020	BUY	$2.25 - $5.8 $176,175 - $454,140	78,300 New	78,300 $400,000
Q4 2019 Jan 09, 2020	SELL	$2.25 - $5.8 $176,175 - $454,140	-78,300 Closed	0 $0
Q2 2019 Jul 29, 2019	BUY	$1.8 - $3.3 $19,800 - $36,300	11,000 Added 16.34%	78,300 $170,000
Q1 2019 Apr 22, 2019	BUY	$2.41 - $5.91 $92,785 - $227,535	38,500 Added 133.68%	67,300 $182,000
Q4 2018 Jan 22, 2019	SELL	$3.94 - $9.7 $7,880 - $19,400	-2,000 Reduced 6.49%	28,800 $138,000
Q2 2018 Jul 17, 2018	SELL	$9.52 - $12.15 $238,000 - $303,750	-25,000 Reduced 44.8%	30,800 $300,000
Q1 2018 May 16, 2018	SELL	$6.7 - $12.95 $14,740 - $28,490	-2,200 Reduced 3.79%	55,800 $587,000
Q3 2017 Oct 16, 2017	BUY	$5.4 - $8.47 $313,200 - $491,260	58,000	58,000 $444,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baxter Bros Inc, based on Form 13F filings with the SEC.

News

Stay updated on Baxter Bros Inc with notifications on news.

Account